-
Something wrong with this record ?
Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3
J. Musil, L. Kutinova, K. Zurkova, P. Hainz, K. Babiarova, J. Krystofova, S. Nemeckova,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1999 to 2016
Freely Accessible Science Journals
from 1999 to 5 calendar years ago
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1999-01-01
Medline Complete (EBSCOhost)
from 1999-01-01 to 2015-11-30
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-01-01 to 1 year ago
PubMed
24556712
DOI
10.1038/cgt.2014.6
Knihovny.cz E-resources
- MeSH
- Antigens, Viral immunology MeSH
- Insulin-Like Growth Factor Binding Protein 3 genetics immunology MeSH
- Immunization methods MeSH
- Human papillomavirus 16 genetics immunology MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Papillomavirus E7 Proteins genetics immunology MeSH
- Promoter Regions, Genetic MeSH
- Virus Replication immunology MeSH
- T-Lymphocytes immunology MeSH
- Antibody Formation MeSH
- Vaccination methods MeSH
- Viral Vaccines immunology pharmacology MeSH
- Vaccinia virus genetics immunology MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
We constructed recombinant vaccinia viruses (VACVs) coexpressing the insulin-like growth factor-binding protein-3 (IGFBP-3) gene and the fusion gene encoding the SigE7Lamp antigen. The expression of the IGFBP-3 transgene was regulated either by the early H5 promoter or by the synthetic early/late (E/L) promoter. We have shown that IGFBP-3 expression regulated by the H5 promoter yielded higher amount of IGFBP-3 protein when compared with the E/L promoter. The immunization with P13-SigE7Lamp-H5-IGFBP-3 virus was more effective in inhibiting the growth of TC-1 tumors in mice and elicited higher T-cell response against VACV-encoded antigen than the P13-SigE7Lamp-TK(-) control virus. We found that high-level production of IGFBP-3 enhanced virus replication both in vitro and in vivo, resulting in more profound antigen stimulation. Production of IGFBP-3 was associated with a higher adsorption rate of P13-SigE7Lamp-H5-IGFBP-3 to CV-1 cells when compared with P13-SigE7Lamp-TK(-). Intracellular mature virions (IMVs) of the IGFBP-3-expressing virus P13-SigE7Lamp-H5-IGFBP-3 have two structural differences: they incorporate the IGFBP-3 protein and they have elevated phosphatidylserine (PS) exposure on outer membrane that could result in increased uptake of IMVs by macropinocytosis. The IMV PS content was measured by flow cytometry using microbeads covered with immobilized purified VACV virions.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15008285
- 003
- CZ-PrNML
- 005
- 20170509084421.0
- 007
- ta
- 008
- 150306s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/cgt.2014.6 $2 doi
- 035 __
- $a (PubMed)24556712
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Musil, Jan $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0210384
- 245 10
- $a Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3 / $c J. Musil, L. Kutinova, K. Zurkova, P. Hainz, K. Babiarova, J. Krystofova, S. Nemeckova,
- 520 9_
- $a We constructed recombinant vaccinia viruses (VACVs) coexpressing the insulin-like growth factor-binding protein-3 (IGFBP-3) gene and the fusion gene encoding the SigE7Lamp antigen. The expression of the IGFBP-3 transgene was regulated either by the early H5 promoter or by the synthetic early/late (E/L) promoter. We have shown that IGFBP-3 expression regulated by the H5 promoter yielded higher amount of IGFBP-3 protein when compared with the E/L promoter. The immunization with P13-SigE7Lamp-H5-IGFBP-3 virus was more effective in inhibiting the growth of TC-1 tumors in mice and elicited higher T-cell response against VACV-encoded antigen than the P13-SigE7Lamp-TK(-) control virus. We found that high-level production of IGFBP-3 enhanced virus replication both in vitro and in vivo, resulting in more profound antigen stimulation. Production of IGFBP-3 was associated with a higher adsorption rate of P13-SigE7Lamp-H5-IGFBP-3 to CV-1 cells when compared with P13-SigE7Lamp-TK(-). Intracellular mature virions (IMVs) of the IGFBP-3-expressing virus P13-SigE7Lamp-H5-IGFBP-3 have two structural differences: they incorporate the IGFBP-3 protein and they have elevated phosphatidylserine (PS) exposure on outer membrane that could result in increased uptake of IMVs by macropinocytosis. The IMV PS content was measured by flow cytometry using microbeads covered with immobilized purified VACV virions.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a tvorba protilátek $7 D000917
- 650 _2
- $a antigeny virové $x imunologie $7 D000956
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidský papilomavirus 16 $x genetika $x imunologie $7 D052162
- 650 _2
- $a imunizace $x metody $7 D007114
- 650 _2
- $a IGFBP-3 $x genetika $x imunologie $7 D018972
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a Papillomavirus E7 - proteiny $x genetika $x imunologie $7 D050725
- 650 _2
- $a promotorové oblasti (genetika) $7 D011401
- 650 _2
- $a T-lymfocyty $x imunologie $7 D013601
- 650 _2
- $a vakcinace $x metody $7 D014611
- 650 _2
- $a virus vakcinie $x genetika $x imunologie $7 D014616
- 650 _2
- $a virové vakcíny $x imunologie $x farmakologie $7 D014765
- 650 _2
- $a replikace viru $x imunologie $7 D014779
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kutinova, L $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Zurkova, K $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Hainz, P $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Babiarová, Katarína $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0118496
- 700 1_
- $a Krystofova, J $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Nemeckova, S $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 773 0_
- $w MED00001038 $t Cancer gene therapy $x 1476-5500 $g Roč. 21, č. 3 (2014), s. 115-25
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24556712 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150306 $b ABA008
- 991 __
- $a 20170509084756 $b ABA008
- 999 __
- $a ok $b bmc $g 1065558 $s 891085
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 21 $c 3 $d 115-25 $i 1476-5500 $m Cancer gene therapy $n Cancer gene ther. $x MED00001038
- LZP __
- $a Pubmed-20150306